췌장암 치료 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of pancreatic cancer treatment Market

The global pancreatic cancer treatment market is witnessing rapid growth due to the rising incidence of cancer and increasing advancements in treatment technologies. The market was valued at USD 3.82 billion in 2025 and is projected to grow to USD 4.42 billion in 2026, eventually reaching USD 14.43 billion by 2034, exhibiting a strong CAGR of 15.95% during the forecast period (2026-2034).

North America dominated the market with a 47.5% share in 2025, driven by advanced healthcare infrastructure, high diagnosis rates, and the presence of leading pharmaceutical companies.

Pancreatic cancer remains one of the deadliest cancers globally, with increasing cases particularly among the geriatric population. The demand for effective therapies, including chemotherapy and targeted drugs, continues to rise as early diagnosis improves worldwide.

Market Trends

One of the key trends shaping the pancreatic cancer treatment market is the growing focus on research and development (R&D). Pharmaceutical companies are investing heavily in developing innovative therapies, including targeted drugs, immunotherapies, and personalized medicine.

The emergence of pipeline drugs and clinical trials is accelerating treatment innovation. For example, ongoing studies on mRNA vaccines and combination therapies are showing promising outcomes in improving patient survival rates.

Additionally, the trend toward precision medicine is gaining traction, allowing treatments tailored to individual genetic profiles, which enhances effectiveness and reduces side effects.

Market Growth Drivers

Rising Prevalence of Pancreatic Cancer

The increasing number of pancreatic cancer cases globally is a major growth driver. Factors such as smoking, aging population, and lifestyle changes contribute to higher incidence rates. This has created a strong demand for advanced treatment solutions.

Increasing R&D and Drug Approvals

Growing investments in R&D and frequent approvals from regulatory authorities are boosting market expansion. Novel therapies such as targeted drugs and immunotherapy combinations are improving survival outcomes and driving adoption.

Advancements in Diagnosis

Improved diagnostic technologies are enabling early detection of pancreatic cancer. As diagnosis rates increase, the demand for treatment drugs rises, significantly contributing to market growth.

Government Support and Awareness Programs

Government initiatives promoting cancer awareness and screening programs are also playing a crucial role in expanding the patient pool and supporting treatment demand globally.

Restraining Factors

Despite strong growth, the market faces certain challenges. The high cost of treatment remains a major barrier, especially in developing regions. Chemotherapy and targeted therapies can be expensive, limiting accessibility for many patients.

Additionally, side effects associated with treatments, such as nausea, fatigue, and complications from radiation therapy, may discourage patients from opting for advanced therapies. These factors are expected to restrain market growth to some extent.

Market Segmentation Analysis

By Type

The market is segmented into exocrine and endocrine pancreatic cancer. The exocrine segment dominates due to its higher prevalence, accounting for the majority of diagnosed cases. It is expected to hold around 97.5% share in 2026.

By Treatment Type

Based on treatment, the market includes chemotherapy, radiation therapy, and others.

• Chemotherapy leads the market as the first-line treatment, expected to account for 48.1% share in 2026.
• Radiation therapy is gaining traction due to advancements in precision technologies.

By End-user

The market is divided into hospitals, clinics, and others.

• Hospitals dominate the segment, with a projected 53.85% share in 2026, due to better infrastructure and availability of advanced treatment options.
• Clinics are also growing steadily with increasing outpatient treatment services.

Regional Insights

North America

North America leads the global market, valued at USD 1.81 billion in 2025 and expected to reach USD 2.11 billion in 2026. Growth is driven by advanced healthcare systems and strong drug pipelines.

Europe

Europe accounted for USD 1.0 billion in 2025 and is projected to reach USD 1.14 billion in 2026, supported by rising awareness and increasing R&D investments.

Asia Pacific

Asia Pacific is a rapidly growing region, valued at USD 0.77 billion in 2025 and expected to reach USD 0.9 billion in 2026. Growth is fueled by improving healthcare infrastructure and rising cancer prevalence.

Rest of the World

Regions such as Latin America and the Middle East & Africa are experiencing gradual growth due to increasing awareness and healthcare investments.

Competitive Landscape

The market is highly competitive, with key players focusing on innovation and strategic collaborations. Major companies include AstraZeneca, Pfizer Inc., Novartis AG, Roche, and Bristol-Myers Squibb.

These companies are investing in new drug development, mergers, and partnerships to strengthen their market position. Continuous product approvals and pipeline advancements are intensifying competition.

Conclusion

The pancreatic cancer treatment market is poised for substantial growth, driven by rising cancer prevalence, advancements in treatment technologies, and increasing investment in R&D. With market value expected to grow from USD 3.82 billion in 2025 to USD 14.43 billion by 2034, the industry presents significant opportunities for stakeholders.

Growth Rate CAGR of 15.95% from 2026-2034

Segmentation

By Type

• Exocrine
• Endocrine

By Treatment Type

• Chemotherapy
• Radiation Therapy
• Others

By End-user

• Hospitals
• Clinics
• Others

By Region

• North America (By Type, By Treatment Type, By End-user, and By Country)
  • U.S. (By Type)
  • Canada (By Type)
• Europe (By Type, By Treatment Type, By End-user, and By Country/Sub-region)
  • Germany (By Type)
  • U.K. (By Type)
  • France (By Type)
  • Spain (By Type)
  • Italy (By Type)
  • Scandinavia (By Type)
  • Rest of Europe (By Type)
• Asia Pacific (By Type, By Treatment Type, By End-user, and By Country/Sub-region)
  • Japan (By Type)
  • China (By Type)
  • India (By Type)
  • Australia (By Type)
  • Southeast Asia (By Type)
  • Rest of Asia Pacific (By Type)
• Latin America (By Type, By Treatment Type, By End-user, and By Country/Sub-region)
  • Brazil (By Type)
  • Mexico (By Type)
  • Rest of Latin America (By Type)
• Middle East & Africa (By Type, By Treatment Type, By End-user, and By Country/Sub-region)
  • GCC (By Type)
  • South Africa (By Type)
  • Rest of Middle East & Africa (By Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence of Pancreatic Cancer, By Key Countries/Regions, 2025
• 4.2. Key Industry Developments - Key Mergers, Acquisitions, and Partnerships
• 4.3. Technologies used in the Diagnosis of the Pancreatic Cancer
• 4.4. Impact of COVID-19 on the Global Pancreatic Cancer Treatment Market

5. Global Pancreatic Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Exocrine
  • 5.1.2. Endocrine
• 5.2. Market Analysis, Insights and Forecast - By Treatment Type
  • 5.2.1. Chemotherapy
  • 5.2.2. Radiation Therapy
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East and Africa

6. North America Pancreatic Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Exocrine
  • 6.1.2. Endocrine
• 6.2. Market Analysis, Insights and Forecast - By Treatment Type
  • 6.2.1. Chemotherapy
  • 6.2.2. Radiation Therapy
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Type
  • 6.4.2. Canada
    • 6.4.2.1. By Type

7. Europe Pancreatic Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Exocrine
  • 7.1.2. Endocrine
• 7.2. Market Analysis, Insights and Forecast - By Treatment Type
  • 7.2.1. Chemotherapy
  • 7.2.2. Radiation Therapy
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. Germany
    • 7.4.1.1. By Type
  • 7.4.2. U.K.
    • 7.4.2.1. By Type
  • 7.4.3. France
    • 7.4.3.1. By Type
  • 7.4.4. Spain
    • 7.4.4.1. By Type
  • 7.4.5. Italy
    • 7.4.5.1. By Type
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Type
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Type

8. Asia Pacific Pancreatic Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Exocrine
  • 8.1.2. Endocrine
• 8.2. Market Analysis, Insights and Forecast - By Treatment Type
  • 8.2.1. Chemotherapy
  • 8.2.2. Radiation Therapy
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Type
  • 8.4.2. China
    • 8.4.2.1. By Type
  • 8.4.3. India
    • 8.4.3.1. By Type
  • 8.4.4. Australia
    • 8.4.4.1. By Type
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Type
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Type

9. Latin America Pancreatic Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Exocrine
  • 9.1.2. Endocrine
• 9.2. Market Analysis, Insights and Forecast - By Treatment Type
  • 9.2.1. Chemotherapy
  • 9.2.2. Radiation Therapy
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Type
  • 9.4.2. Mexico
    • 9.4.2.1. By Type
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Type

10. Middle East & Africa Pancreatic Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Exocrine
  • 10.1.2. Endocrine
• 10.2. Market Analysis, Insights and Forecast - By Treatment Type
  • 10.2.1. Chemotherapy
  • 10.2.2. Radiation Therapy
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals
  • 10.3.2. Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Type
  • 10.4.2. South Africa
    • 10.4.2.1. By Type
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. AstraZeneca
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Novartis AG
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Genentech (F. Hoffmann-La Roche Ltd)
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Bristol-Myers Squibb Company
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Ipsen Pharma
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Oncolytics Biotech, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. TME Pharma
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Erytech Pharma
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)